Format

Send to

Choose Destination
Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

IgM myeloma: A multicenter retrospective study of 134 patients.

Author information

1
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
2
Jagiellonian University Medical College, Krakow, Poland.
3
Masaryk University, Brno, Czech Republic.
4
Professor Edgar Santos University Hospital, Salvador, Brazil.
5
University Hospital of Salamanca, Salamanca, Spain.
6
Mayo Clinic, Rochester, Minnesota, USA.
7
Nantes University Hospital, Nantes, France.
8
Washington University School of Medicine, Saint Louis, Missouri, USA.
9
Le Scotte Hospital, Siena, Italy.
10
University of Ostrava and Faculty Hospital Ostrava, Ostrava, Czech Republic.
11
Santa Casa de Misericordia Hospital, Sao Paulo, Brazil.
12
Weill Cornell Medical College, New York, New York, USA.
13
Charles University Hospital, Hradec Kralove, Czech Republic.
14
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
15
Karolinska University Hospital, Stockholm, Sweden.
16
Palacky University Hospital, Olomouc, Czech Republic.
17
University Hospital Brno, Brno, Czech Republic.
18
Rhode Island Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
19
Charles University Hospital, Prague, Czech Republic.
20
Warsaw Medical University, Warsaw, Poland.

Abstract

IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL-1 with 19% of patients presenting with levels >6,000 mg dL-1 . International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

PMID:
28383205
DOI:
10.1002/ajh.24753
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center